Pnd21 Cost-Effectiveness of Rasagiline Compared to Other First Line Treatment Options of Early Parkinson's Disease in the United States

Farkouh, R; Wilson, Rachel; Tarrants, ML; Castelli-Haley, Jane; Armand, C.

doi:10.1016/s1098-3015(10)74815-4

Cited by 4 publications

(36 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2010 values] that was well within the commonly accepted willingness-to-pay threshold of $US50,000/QALY (Table 5) [50]. The cost effectiveness of rasagiline was robust to variations in key parameters in one-way sensitivity analysis.…”

Section: Pharmacoeconomic Considerationssupporting

confidence: 57%

“…Three fully published, modelled, cost-utility analyses have assessed the cost effectiveness of therapy with oral rasagiline 1 mg/day in patients with early [49,50] or advanced [51] Parkinson's disease (see Table 5). All three studies used a Markov health-state transition model over a 2-year [51] or 5-year [49,50] time horizon from a US managed care perspective [50], a UK healthcare payer perspective [49] or a societal perspective in Finland [51].…”

Section: Pharmacoeconomic Considerationsmentioning

confidence: 99%

“…All three studies used a Markov health-state transition model over a 2-year [51] or 5-year [49,50] time horizon from a US managed care perspective [50], a UK healthcare payer perspective [49] or a societal perspective in Finland [51].…”

Section: Pharmacoeconomic Considerationsmentioning

confidence: 99%

See 2 more Smart Citations

Rasagiline: A Review of Its Use in the Treatment of Idiopathic Parkinson’s Disease

McCormack

2014

CNS Drugs

View full text Add to dashboard Cite

Rasagiline (Azilect(®)) is an oral, second-generation, selective, irreversible monoamine oxidase-B (MAO-B) inhibitor approved in the US for the treatment of Parkinson's disease. In randomized, controlled trials, oral rasagiline 1 mg once daily was superior to placebo in the symptomatic treatment of early Parkinson's disease, both as monotherapy or as an adjunct to dopamine agonists. Comparisons of early-start and delayed-start treatment suggested a disease-modifying effect for rasagiline, but the results were equivocal. Rasagiline 0.5 or 1 mg/day was also superior to placebo as adjunctive therapy to levodopa in Parkinson's disease patients with motor fluctuations. Rasagiline was generally well tolerated in clinical trials, displaying a placebo-like tolerability profile in several studies. Cost-utility studies predicted that rasagiline, either as monotherapy or adjunctive therapy, would be a cost-effective treatment option. Therefore, oral rasagiline is a valuable therapeutic option for use in all stages of Parkinson's disease.

show abstract

Section: Pharmacoeconomic Considerationssupporting

confidence: 57%

Section: Pharmacoeconomic Considerationsmentioning

confidence: 99%

See 1 more Smart Citation

Rasagiline: A Review of Its Use in the Treatment of Idiopathic Parkinson’s Disease

McCormack

2014

CNS Drugs

View full text Add to dashboard Cite

show abstract

“…The most common treatment for counteracting the incipient symptoms of PD is oral monotherapy medication (i.e., levodopa, DA, or rasagiline), which is effective in reducing motor fluctuations. In the USA, researchers compared the cost‐effectiveness of rasagiline versus DA (ropinirole XL, pramipexole, generic ropinirole) or levodopa as initial therapies in PD . Treatment with rasagiline led to more QALYs (3.45 vs. 3.34, 3.34, 3.34 for the DAs respectively, and 3.21 for levodopa), fewer patients with dyskinesia (38% and 73% respectively), and lower costs than ropinirole XL, pramipexole, and levodopa, thus dominating the alternatives.…”

Section: Resultsmentioning

confidence: 99%

“…Standard care or best medical treatment, including mostly oral levodopa, was used as the main comparator across interventions, which eased the comparability of the outcomes. However, there were studies that compared the results within the same category of interventions …”

Section: Discussionmentioning

confidence: 99%

Economic Evaluation of Interventions in Parkinson's Disease: A Systematic Literature Review

Afentou

Jarl

Gerdtham

et al. 2019

Movement Disord Clin Pract

View full text Add to dashboard Cite

Background Parkinson's disease (PD) management comprises of drug treatments, surgery, and physical activity/occupational therapies to relieve PD's symptoms. The aim of this study is twofold; first, to appraise recent economic evaluation studies on PD management in order to update the existing knowledge; and second, to facilitate decision making on PD management by assessing the cost‐effectiveness of all types of PD interventions. Methods A systematic search for studies published between 2010 and 2018 was conducted. The inclusion and exclusion of the articles were based on criteria relevant to population, intervention, comparison, outcomes, and study design (PICO). The reporting quality of the articles was assessed according to Consolidated Health Economic Evaluation Reporting Standards. Results Twenty‐eight articles were included, 10 of which were evaluations of drug treatments, 10 deep brain stimulation (DBS), and eight physical/occupational therapies. Among early‐stage treatments, Ti Ji dominated all physical activity interventions; however, its cost‐effectiveness should be further explored in relation to its duration, intensity, and frequency. Multidisciplinary interventions of joint medical and nonmedical therapies provided slightly better health outcomes for the same costs. In advanced PD patients, adjunct drug treatments could become more cost‐effective if introduced during early PD and, although DBS was more cost‐effective than adjunct drug therapies, the results were time‐bound. Conclusions Conditionally, certain PD interventions are cost‐effective. However, PD progression differs in each patient; thus, the cost‐effectiveness of individually tailored combinations of interventions that could provide more time in less severe disease states and improve patients’ and caregivers’ quality of life, should be further explored.

show abstract

A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease

Jost

2022

J Neural Transm

View full text Add to dashboard Cite

Since the 1980s, the MAO-B inhibitors have gained considerable status in the therapy of the Parkinson’s disease. In addition to the symptomatic effect in mono- and combination therapies, a neuroprotective effect has repeatedly been a matter of some discussion, which has unfortunately led to a good many misunderstandings. Due to potential interactions, selegiline has declined in significance in the field. For the MAO-B inhibitor safinamide, recently introduced to the market, an additional inhibition of pathological release of glutamate has been postulated. At present, rasagiline and selegiline are being administered in early therapy as well as in combination with levodopa. Safinamide has been approved only for combination therapy with levodopa when motor fluctuations have occurred. MAO-B inhibitors are a significant therapeutic option for Parkinson’s disease, an option which is too often not appreciated properly.

show abstract

Pnd21 Cost-Effectiveness of Rasagiline Compared to Other First Line Treatment Options of Early Parkinson's Disease in the United States

Cited by 4 publications

References 7 publications

Rasagiline: A Review of Its Use in the Treatment of Idiopathic Parkinson’s Disease

Rasagiline: A Review of Its Use in the Treatment of Idiopathic Parkinson’s Disease

Economic Evaluation of Interventions in Parkinson's Disease: A Systematic Literature Review

A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease

Contact Info

Product

Resources

About